HIGHLIGHTS
- who: Randall C. Dere et al. from the Bristol Myers Squibb, United States have published the paper: Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkinu2019s lymphoma, in the Journal: (JOURNAL)
- what: The overall risk of generating an immune_response in patients treated with polatuzumab vedotin is considered low based on a variety of considerations, including a comprehensive immunogenicity risk ac, antibody conjugated; ADA, anti-drug antibody; AUC, area under the concentration-time curve; Cmax, maximum concentration; CV, coefficient of variation; CI, confidence interval; GM, geometric mean; GMR . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.